Comparison of Body Habitus in Patients With Pulmonary Arterial Hypertension Enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management With Normative Values From the National Health and Nutrition Examination Survey

著录项

• 来源
  《Mayo Clinic Proceedings 》 |2011年第2期| p.105-112| 共8页
• 作者

  Charles D Burger Aimee J Foreman Dave P Miller Robert E Safford Michael D McGoon David B Badesch;

  展开▼
• 作者单位

  CHARLES D. BURGER, MD, AIMEE J. FOREMAN, MA, DAVE P. MILLER, MS, ROBERT E. SAFFORD, MD, PHD, MICHAEL D. MCGOON, MD, AND DAVID B. BADESCH, MDFrom the Departments of Critical Care Medicine and Pulmonary Medicine (C.D.B.) and Division of Cardiovascular Diseases (R.E.S.), Mayo Clinic, Jacksonville, FL, ICON Clinical Research, San Francisco, CA (AJ. F, D.RM.), Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (M. D.M.), and Divisions of Pulmonary Sciences and Critical Care Medicine and Cardiology, University of Colorado Health Sciences Center, Denver (D.B.B.).Ms Foreman and Mr Miller are employed by ICON Clinical Research, a company that receives research support from Actelion and other pharmaceutical companies. Dr McGoon serves as a consultant with Actelion, Gilead, Lung Rx, and Medtronic, has received grants from Gilead and Medtronic, and has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Dr Badesch has received honoraria for service on steering committees and/or advisory boards for Actelion, Arena, Bayer, lkaria, Gilead, Encysive Pharmaceuticals, Pfizer, GlaxoSmlthKllne, Lung Rx, United Therapeutics, Eli Lilly and Company, Blogen Idee, and mondoBIOTECH, has received grants from Actelion, Gilead, Encysive Pharmaceuticals, Pfizer, United Therapeutics, Lung Rx, Ell Lilly and Company, and the National Institutes of Health, National Heart, Lung, and Blood Institute, has previously been deposed in appetite suppressant litigation, serving as both a treating physician and an expert witness, and has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion.The REVEAL registry is sponsored by Actelion Pharmaceuticals US, Inc.This article is freely available on publication, because the authors have chosen the immediate access option.Individual reprints of this article are not available. Address correspondence to Charles D. Burger, MD, Division of Pulmonary Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224 (burger.charles@mayo.edu).© 2011 Mayo Foundation for Medical Education and Research,;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词